SCHEMBL8281118

SCHEMBL8281118

Cc1ccc(CCN2CCCC2)cn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.61
CYP1A2 P05177 2/20 0.56
CYP2D6 P10635 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.53
MBTD1 Q05BQ5 1/20 0.53
L3MBTL3 Q96JM7 1/20 0.53
TDP1 Q9NUW8 1/20 0.51
CYP3A4 P08684 1/20 0.50
SLC6A3 Q01959 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
SIGMAR1 Q99720 3/20 0.49
HRH1 P35367 2/20 0.46
BCHE P06276 1/20 0.46
ADRA2A P08913 1/20 0.46
DRD2 P14416 1/20 0.46
ADRA2B P18089 1/20 0.46
ADRA2C P18825 1/20 0.46
ACHE P22303 1/20 0.46
HRH2 P25021 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20038476 0.85 SIGMAR1 (0.51) HRH3CYP1A2CYP2D6CYP3A4SLC6A3
SCHEMBL4554100 0.82 CHRNB2 (0.56) HRH3L3MBTL1MBTD1L3MBTL3KDM4E
SCHEMBL12334539 0.81 HRH3 (0.59) HRH3CYP2D6KDM4EALDH1A1
SCHEMBL21657796 0.80 CYP1A2 (0.48) HRH3CYP1A2CYP2D6L3MBTL1MBTD1
SCHEMBL4625412 0.79 HRH3 (0.54) HRH3CYP1A2CYP2D6L3MBTL1MBTD1
SCHEMBL12049097 0.79 CHRNB2 (0.51) HRH3KDM4EALDH1A1HRH1
SCHEMBL227159 0.78 HRH3 (0.56) HRH3CYP1A2CYP2D6L3MBTL1MBTD1
SCHEMBL20749289 0.77 TSHR (0.55) CYP1A2KDM4EALDH1A1SIGMAR1HRH1
SCHEMBL7399231 0.76 HRH3 (0.50) HRH3CYP1A2CYP2D6L3MBTL1MBTD1
SCHEMBL13164030 0.76 HRH3 (1.00) HRH3CYP1A2L3MBTL1MBTD1L3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129844-A1 N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF ASTRAZENECA AB 2012-05-24 US disclosed
US-20120129844-A1 N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF ASTRAZENECA AB 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129844-A1 N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 HRH3 3825/4885CYP1A2 58/4885CYP2D6 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.